|
| [February 04, 2013] |
 |
US FDA Extends License of the GVK BIO Biomarker Database
HYDERABAD, India --(Business Wire)--
GVK
Biosciences (GVK BIO) today announced that it is extending its
Clinical Biomarker Database (GOBIOM) license to the Biomarker
Qualification Group of the US Food and Drug Administration (US FDA). The
GOBIOM database, which has the latest and recently updated information
on all the biomarkers reported in various clinical and preclinical
studies, will be beneficial to the US FDA in its Biomarker Qualification
Process.
The GOBIOM database is a comprehensive compilation of all the clinically
evaluated, exploratory and preclinical biomarkers associated with
different therapeutic areas reported in global clinical trials, clinical
and preclinical studies. GOBIOM contains information on 20,000
biomarkers comprising biochemical, genomic, imaging, metabolite,
cellular and physiological markers, along with multiple data points
comprising experimental, analytical, clinical and statistical data with
their qualifications under different medical interventions.
Sreeni Devidas, Vice President, Sales & Marketing, Informatics (News - Alert), said, "The
collaboration with the US FDA has helped GVK
BIO in developing the safety biomarker content in GOBIOM. The
interconnectivity between organ toxicities to the drug, dose nd
population was developed with equal emphasis on its preclinical
qualification. Biomarker analysis tools were integrated into the
database in a manner that has facilitated the user to make a comparative
analysis between the biomarkers of their interest. We look forward to
continue working and collaborating with the FDA with a view to enhancing
the utility of the product further."
About GVK BIO
GVK
Biosciences (GVK BIO) is Asia's leading discovery, research and
development organization providing a broad spectrum of services,
stand-alone and integrated, across the R&D value chain. Our discovery
services consist of Chemistry,
Biology
and Informatics;
the development services include Clinical
Research, Clinical
Pharmacology and Process
R&D. GVK
BIO's diverse portfolio and global clientele comprising more than
200 customers includes some of the global leading organizations in the
fields of pharmaceuticals, biotechnology, agro, life-sciences as well as
prestigious academic institutions. Please visit us at www.gvkbio.com
to know more.

[ Back To Technology News's Homepage ]
|